
Poly Medicure Q1 FY27 Results: Revenue Rs 525 Cr, PAT Rs 83 Cr and Key Highlights
Poly Medicure Q1 FY27 results declared August 7, 2026. Revenue Rs 525 Cr (+30.30% YoY). PAT Rs 83 Cr (-8.76% YoY). CMP Rs 1693.8 (-0.91%).
Updated: 10 Aug 2026 • 12:17 pm
Posted by:

Poly Medicure Q1 FY27 results were announced on August 7, 2026, consolidated. Revenue grew +30.30% YoY to Rs 525 Cr from Rs 403 Cr in Q1 FY26. The broader BSE Healthcare index reflected mixed sentiment during the quarter.
Operating profit stood at Rs 88 Cr (+7.20% YoY). PAT came in at Rs 83 Cr (-8.76% YoY), offering a comprehensive view of how Poly Medicure is navigating the current medical devices environment.
Click Here – Get Free Investment Predictions
Poly Medicure Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | YoY Change |
|---|---|---|---|
| Poly Medicure Revenue | 525 | 403 | +30.30% |
| Operating Profit | 88 | 82 | +7.20% |
| Net Profit (PAT) | 83 | 91 | -8.76% |
| Reporting Basis | Consolidated | ||
Poly Medicure Q1 FY27 Performance Analysis
Check the Univest Screener for Live Data on This Stock
Poly Medicure Q1 FY27 results reflect modest fundamentals across key financial metrics. Revenue momentum stayed robust with the top line reaching Rs 525 Cr for the April to June 2026 quarter.
Operating profit expanded +7.20% YoY to Rs 88 Cr. This indicates improving cost efficiency and better product mix.
PAT of Rs 83 Cr marks a -8.76% YoY movement in Poly Medicure Q1 FY27 results. Investors monitoring Poly Medicure Q1 FY27 results will note this as a key FY27 performance milestone.
Key Business Factors in Poly Medicure Q1 FY27 Results
Revenue Expansion Driving Top-Line Growth
Poly Medicure Q1 FY27 results show top-line strength with revenue growing +30.30% YoY to Rs 525 Cr from Rs 403 Cr in Q1 FY26. Order execution momentum and market share gains in the Medical Devices segment fuelled this expansion.
Operating Leverage and Margin Improvement
Operating profit in Poly Medicure Q1 FY27 results improved +7.20% YoY to Rs 88 Cr, reflecting better cost control, improving product mix, and operating leverage as the company scales volumes.
PAT Performance and Profitability Trend
Net profit (PAT) in Poly Medicure Q1 FY27 results stood at Rs 83 Cr ((-8.76% YoY)). Near-term PAT moderation is being managed through cost optimisation and revenue diversification.
Dividend Details
No dividend was announced alongside Poly Medicure Q1 FY27 results. The company is likely channelling earnings toward business reinvestment and working capital needs.
FY27 Outlook for Poly Medicure
Following Poly Medicure Q1 FY27 results, management has reiterated a recovery-focused strategy targeting operational efficiencies, cost rationalisation, and revenue diversification. The pace of recovery in the medical devices segment will be a key monitorable for investors tracking Poly Medicure Q1 FY27 results. Consult a SEBI-registered financial advisor before making decisions.
Poly Medicure Stock Performance After Q1 FY27 Results
Download the Univest iOS App or Univest Android App to track Poly Medicure live price and get daily stock recommendations.
Poly Medicure shares were trading lower at Rs 1693.8 (-0.91%) on August 7, 2026, reflecting investor sentiment on the Poly Medicure Q1 FY27 results and near-term sector outlook. The CMP of Rs 1693.8 on the results date reflects broader market and sector sentiment in the medical devices space.
Key Risks for Poly Medicure
Sector-Specific Risks
Regulatory approvals for new products and competition from imported devices.
Valuation and Earnings Risk
Sustained earnings pressure may delay re-rating; near-term earnings visibility remains limited.
Operational and Financial Risk
Subsidiary-level losses or underperforming overseas operations could drag consolidated PAT lower.
Conclusion
Poly Medicure Q1 FY27 results reflect modest performance with revenue at Rs 525 Cr and PAT at Rs 83 Cr on a Consolidated basis. Operating leverage and sector tailwinds will determine the FY27 growth trajectory. Investors should review management commentary and sector developments before taking positions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Poly Medicure Q1 FY27 Results
When were Poly Medicure Q1 FY27 results declared?
Ans. Poly Medicure Q1 FY27 results were declared on August 7, 2026, covering the April to June 2026 quarter on a Consolidated basis.
What was Poly Medicure revenue in Q1 FY27?
Ans. Poly Medicure Q1 FY27 results show revenue of Rs 525 Cr, +30.30% compared to Rs 403 Cr in Q1 FY26.
What was Poly Medicure PAT in Q1 FY27?
Ans. Net profit in Poly Medicure Q1 FY27 results was Rs 83 Cr, -8.76% year-on-year.
Did Poly Medicure declare a dividend in Q1 FY27?
Ans. No dividend was announced alongside Poly Medicure Q1 FY27 results. Check the official NSE and BSE announcements for future dividend declarations.
What is the FY27 outlook for Poly Medicure?
Ans. Management has guided operational restructuring and return to profitability for FY27. Sector trends and order visibility will be key monitorables for investors.
How did Poly Medicure stock react to Q1 FY27 results?
Ans. Poly Medicure shares were trading lower at Rs 1693.8 (-0.91%) on August 7, 2026 following the Poly Medicure Q1 FY27 results. Always consult a SEBI-registered financial advisor before acting on stock price movements.
Recent Articles

Krishana Phoschem Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast
10 August 2026

Vindhya Telelinks Ltd. (VINDHYATEL): Vindhya Telelinks Share Price Rises 9.54% Today as Small Cap Stock Enters Top Gainers
10 August 2026

LMW Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast
10 August 2026

Diffusion Engineers Ltd. (DIFFNKG) Share Price Falls 8.04% to Rs 404.65
10 August 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Krishana Phoschem Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast
Vindhya Telelinks Ltd. (VINDHYATEL): Vindhya Telelinks Share Price Rises 9.54% Today as Small Cap Stock Enters Top Gainers
LMW Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast
Diffusion Engineers Ltd. (DIFFNKG) Share Price Falls 8.04% to Rs 404.65
KRM Ayurveda Ltd. (KRMAYURVED-SM): KRM Ayurveda Share Price Rises 10.6% as Micro Cap Stock Clears Threshold
Popular this week
Tourism Finance Corporation Of India Ltd. (TFCILTD) Share Price Within 2% of 52-Week High

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





